Industry Outlook

The Extracorporeal Membrane Oxygenation market accounted for USD 545.2 Million in 2024 and is expected to reach USD 903.6 Million by 2035, growing at a CAGR of around 4.7% between 2025 and 2035. Extracorporeal Membrane Oxygenation (ECMO) Market is related to the development, production, and distribution of ECMO equipment and associated services. It is a life-support system that is used to supply oxygen to blood outside the body when the heart and lungs fail to function properly. It is boosted by increasing rates of respiratory and cardiovascular diseases and technological advancements in the supply of surgical procedures. This market is boosted by increasing rates of respiratory and cardiovascular hospitals’ emergency services, such as respiratory distress, sudden cardiac death, or during surgery diseases. 

Report Scope:

Market Dynamics

Government funding and initiatives support Extracorporeal Membrane Oxygenation (ECMO) research and development programs.

The government takes initiatives and funding for the growth and development of the ECMO market. The healthcare technology improvements led to increased usage of these systems within the healthcare community. The rising rates of cardiovascular and respiratory diseases increase the use of extracorporeal life support (ECLS) and enhance the demand in healthcare. Government programs and initiatives support to reduce healthcare costs while improving patient mortality rates are an additional factor in the increased usage. Additionally, the increase in dedicated ECMO facilities around the world indicates support from government administrators toward the healthcare system. With a focus on medical technologies such as ECMOs, the European Commission established Horizon and provided more than 80 billion euros for research and education.

Shortage of trained healthcare professionals limits Extracorporeal Membrane Oxygenation (ECMO) market availability in hospitals.

One of the major obstacles limiting the Extracorporeal Membrane Oxygenation (ECMO) Market is a shortage of qualified medical experts. This is complex and resource-consuming in nature and requires highly specialized skills in its operation and managing patients. This technological advancement has not reached many hospitals because this treatment is administered by a small number of trained personnel. Furthermore, becoming certified to provide ECMO services requires time and money, which makes one less appealing to different healthcare facilities. This results in restricted capacity in areas where hospitals are capable of creating ECMO services, thus affecting their growth on a larger scale.

AI integration into the Extracorporeal Membrane Oxygenation (ECMO) market improves monitoring and decision-making.

Artificial intelligence brings excellent opportunities to the Extracorporeal Membrane Oxygenation (ECMO) Market through efficient monitoring and decision-making. AI algorithms integrate patient health and system performance data with greater precision by analyzing real-time data from ECMO machines. Early detection of potential complications requires immediate intervention or individualized treatment plan modifications. By supporting patient requirements, AI-driven predictive analytics enhance clinical outcomes while optimizing ECMO settings. The use of machine learning models in automating routine tasks helps to offload cognitive burdens from doctors’ minds and minimize human errors associated with them. Integrating this technology into ECMO systems is one of the most significant steps toward improving the effectiveness of life-sustaining therapies as demand for advanced medical technologies continues to rise.

Industry Experts Opinion

"Patients with novel coronavirus have noticeable damage in their respiratory system, and if we can use ECMO to pump oxygen into their bloom streams, it will help their lungs rest and recover faster,"

• Ma Xin, vice-president of Huashan Hospital of Fudan University in Shanghai.

“The whole idea of ECMO therapy is to give adequate rest to the heart and lungs, come up with intervention strategies to make them better, but at the same time support rest of the vital organs, which still need the blood supply and the oxygen”

• Lovkesh Arora, MD, an anesthesiologist and critical care intensivist with the University of Iowa Health Care.

Segment Analysis

Based on the product type, the Extracorporeal Membrane Oxygenation Market is classified into ECMO Machines [Portable Devices and Static Devices] and Software. The most dominant segment in this market constitutes ECMO machines, especially portable devices. With these devices, patients can receive life-saving treatment while being transported or in various healthcare settings, such as ICUs or emergency departments. Technical innovations made them more efficient and user-friendly for different patients’ needs. This increasing preference for these devices is due to their substantial contribution towards improving patient outcomes in terms of emergency care and management of chronic diseases

Based on the application, the Extracorporeal Membrane Oxygenation Market is classified into Respiratory Applications, Cardiac Applications, and Extracorporeal Cardiopulmonary Resuscitation (ECPR). The leading segment of this market is respiratory applications, due to the prevalence of severe airway diseases including acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and viral infections such as COVID-19. In severely affected individuals, ECMO is important when other regular ventilation techniques are unable to provide sufficient oxygen. The use of ECMO in respiratory care has become increasingly popular over time due to greater awareness regarding its benefits and developments in this technology. Other drivers include improvements in healthcare systems across various nations.

Regional Analysis

The North American Extracorporeal Membrane Oxygenation (ECMO) market is characterized by significant technological advancement and increasing adoption rates. The demand is due to the prevalence of respiratory and cardiac conditions such as acute respiratory distress syndrome (ARDS) and cardiogenic shock. The market is supported by a robust healthcare system, including hospitals and specialized facilities that provide ECMO systems. The expansion of ECMO is driven by growing awareness of critical care. Key players focus on strategic research and development, collaborations, and acquisitions to maintain their competitive edge.

The Extracorporeal Membrane Oxygenation (ECMO) market in Europe is experiencing steady growth driven by increasing cases of respiratory and cardiac diseases, including acute respiratory distress syndrome (ARDS) syndrome and heart failures. Countries like Germany, the UK, and France with strong medical infrastructure are investing in advanced life support technologies such as ECMO. Its adoption is also supported by increasing awareness and survival rates among patients in critical care.

Competitive Landscape

In the highly competitive world of the Extracorporeal Membrane Oxygenation (ECMO) Market, leading players are driving advancements in critical care technologies. With their advanced ECMO systems and global reach, major players like Terumo Corporation, Getinge AB, LivaNova PLC, and Medtronic Plc influence an important segment of this market. MicroPort Scientific Corporation and Xenios AG are expanding their product portfolios through partnerships. LivaNova is adding children's oxygenator technologies to its portfolio of cardiopulmonary products and Getinge introduced advanced ECMO systems to improve patient survival. Similarly, by developing affordable devices, some recent entrants like Alung Technologies and CytoSorbents Corporation have generated competition in the market. These allow expansion and create innovation in patient care and longer-term development.

Extracorporeal Membrane Oxygenation Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In July 2023, during the ASAIO Conference, China's medical technology innovation was showcased with the introduction of BreathMo, a cutting-edge ECMO system. By meeting the specific medical needs of Chinese patients, this state-of-the-art maglev technology represents a significant scientific breakthrough.
• In April 2023, the FDA granted Abbott two more clearances for their highly regarded life support system, specifically the CentriMag Blood Pump. The FDA's expanded indication permits adults who are dependent on extracorporeal membrane oxygenation (ECMO), a crucial life support technique for people with heart and lung problems, to use the medication for longer periods.
• In February 2023, China introduced its extracorporeal membrane oxygenation (ECMO), or artificial lung/heart system, using rocket servo technology. 

Report Coverage:

By Product Type

• ECMO Machines
  • Portable Devices
  • Static Devices
• Software

By Application

• Respiratory Applications
• Cardiac Applications
• Extracorporeal Cardiopulmonary Resuscitation (ECPR)

By Modality

• Veno-Arterial
• Veno-Venous
• Others

By Patient Type

• Neonates
• Pediatric
• Adult

By End-User

• Hospitals
• Clinics and Ambulatory Surgical Centers
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Medtronic Plc
• Getinge AB
• LivaNova PLC
• MicroPort Scientific Corporation
• Abbott Laboratories
• Terumo Corporation
• Alung Technologies, Inc.
• EUROSETS S.r.l.
• Nipro Corporation
• Fresenius Medical Care AG & Co. KGaA
• Baxter International Inc.
• Orion Health Pty Ltd.
• Xenios AG
• Biomedica Beteiligungs- und Handels GmbH
• CytoSorbents Corporation

Frequently Asked Questions (FAQs)